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This was a retrospective cohort study that was conducted in a single centre. The patients were identified from those who had undergone either LCBDE or IOES. The data were then retrospectively compared. No follow-up was performed.
Analysis of effectiveness
All of the patients included in the initial study sample were considered in the effectiveness analysis. The health outcomes used were: the rate of ductal stone clearance, the rate of conversion to open surgery (which was considered as a failure), the rate of morbidity associated with the procedure, operative time, hospital stay, and postoperative stay.
The study groups were comparable at baseline in terms of their demographic and clinical characteristics.
Effectiveness results
The rates of ductal stone clearance were equivalent in the two groups, 88% in the LCBDE group and 89% in the IOES group, (p=0.436).
The rate of conversion to open surgery was 4.4% in the LCBDE group versus 8.8% in the IOES group, (p=0.381).
The rates of morbidity associated with the procedure were 6.7% (LCBDE group) and 12.3% (IOES group), respectively, (p=0.336).
The median operative time was 180 minutes (25 -75% quartile range: 130 -220) in the LCBDE group versus 155 minutes (25 -75% quartile range: 130 -210) in the IOES group, (p=0.661).
The median length of hospital stay was longer in the LCBDE group (7 days, 25 -75% quartile range: 6 -9) than in the IOES group (6 days, 25 -75% quartile range: 4.5 -8), (p=0.041).
The median postoperative stay was longer in the LCBDE group (4 days, 25 -75% quartile range: 3 -6) than in the IOES group (3 days, 25 -75% quartile range: 2 -5), (p=0.024).
Clinical conclusions
The effectiveness study showed that LCBDE and IOES were similarly effective, but that hospital stay was significantly shorter in IOES patients.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was used in the economic analysis. In effect, a cost-consequences analysis was carried out.
intraoperative cholangiography, and additional stay or procedures. The cost/resource boundary of the study was not reported. Resource consumption was estimated from actual data that referred to the patients involved in the effectiveness study from November 1999 to October 2000. The costs were estimated from the hospital admissions department. The price year was not reported.
Statistical analysis of costs
The Mann-Whitney test and chi-squared test were used to test the statistical significance of differences in the estimated costs.
Indirect Costs
The indirect costs were not considered in the economic evaluation.
Currency
Chinese yuan (Yuan).
Sensitivity analysis
No sensitivity analyses were performed.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
The median cost per patient was Yuan 11, 822) in the LCBDE group and Yuan 15,466 (25 -75% quartile range: 13,555 -17,689) in the IOES group. The difference was statistically significant, (p=0.000).
Among patients with complications, the median cost per patient was Yuan 15, 895) in the LCBDE group and Yuan 23, 289) in the IOES group. The difference was statistically significant, (p=0.000).
Among patients without complications, the median cost per patient was Yuan 11, 380) in the LCBDE group and Yuan 14,955 (25 -75% quartile range: 12,650 -16,793) in the IOES group. The difference was statistically significant, (p=0.000).
The differences between LCBDE and IOES patients reached statistical significance in patients with or without complications. However, within the LCBDE group, there was no statistically significant difference in costs between patients with and without complications, while within the IOES group, the median cost per patient with complications was significantly higher than the median cost per patient without complications.
Synthesis of costs and benefits
Not relevant as a cost-consequences analysis was carried out.
